Daiwa Securities Group Inc. Sells 18,926 Shares of Moderna, Inc. (NASDAQ:MRNA)

Daiwa Securities Group Inc. lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 27.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 51,265 shares of the company’s stock after selling 18,926 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Moderna were worth $2,132,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of MRNA. State Street Corp increased its position in Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares during the period. Wellington Management Group LLP increased its holdings in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after buying an additional 906,114 shares during the period. Amundi increased its holdings in Moderna by 79.8% in the 4th quarter. Amundi now owns 1,206,273 shares of the company’s stock valued at $52,075,000 after buying an additional 535,273 shares during the period. Two Sigma Advisers LP bought a new stake in Moderna in the 3rd quarter valued at $23,825,000. Finally, Douglas Lane & Associates LLC increased its holdings in Moderna by 62.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after buying an additional 298,715 shares during the period. Institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MRNA. Piper Sandler reissued an “overweight” rating and issued a $69.00 price target (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Berenberg Bank boosted their price target on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Evercore ISI set a $50.00 price target on shares of Moderna in a report on Friday, February 14th. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and lowered their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Finally, Morgan Stanley reduced their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $59.60.

Moderna Trading Up 0.9 %

Shares of NASDAQ MRNA opened at $34.62 on Friday. The company has a market cap of $13.36 billion, a price-to-earnings ratio of -3.73 and a beta of 1.86. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The stock has a 50-day moving average price of $35.94 and a two-hundred day moving average price of $47.59.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.